专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0170204A2 HIGHLY SELECTIVE INHIBITORS OF THE UROKINASE PLASMINOGEN ACTIVATOR 审中-公开
标题翻译：尿激酶型纤溶酶原激活剂高选择性抑制剂
公开(公告)号：WO0170204A2
公开(公告)日：2001-09-27
申请号：PCT/EP0102989
申请日：2001-03-15
申请人： WILEX BIOTECHNOLOGY GMBH , MAX PLANCK GESELLSCHAFT , MAGDOLEN VIKTOR , SPERL STEFAN , STUERZEBECHER JOERG , WILHELM OLAF , ARROYO DEPRADA NURIA , MORODER LUIS , HUBER ROBERT , JACOB UWE , BODE WOLFRAM
发明人： MAGDOLEN VIKTOR , SPERL STEFAN , STUERZEBECHER JOERG , WILHELM OLAF , ARROYO-DEPRADA NURIA , MORODER LUIS , HUBER ROBERT , JACOB UWE , BODE WOLFRAM
IPC分类号： A61K31/155 , C07C279/18 , A61K31/00
CPC分类号： C07C279/18 , A61K31/155 , C07C2603/74
摘要： The invention relates to novel selective inhibitors of the urokinase plasminogen activator (uPA, EC 3.4.21.31), of the arylguanidine type.
摘要翻译：本发明涉及尿激酶型纤溶酶原激活物（uPA，EC 3.4.21.31）从Arylguanidintyp的新型选择性抑制剂。

2. 发明申请

WO2005051999A3 SUBSTANCE BINDING HUMAN IGG FC RECEPTOR IIB 审中-公开
标题翻译：物质绑定人类IGG FC受体IIB
公开(公告)号：WO2005051999A3
公开(公告)日：2005-11-24
申请号：PCT/EP2004013450
申请日：2004-11-26
申请人： MAX PLANCK GESELLSCHAFT , HUBER ROBERT , SONDERMANN PETER , JACOB UWE , WENDT KERSTIN , CHIARA CABRELE , MORODER LUIS
发明人： HUBER ROBERT , SONDERMANN PETER , JACOB UWE , WENDT KERSTIN , CHIARA CABRELE , MORODER LUIS
IPC分类号： C07K14/735 , C07K16/28 , C07K14/705 , A61K38/17 , A61K39/00 , C12N15/12 , C12N15/63 , G01N33/53 , G01N33/68
CPC分类号： C07K14/70535 , A61K2039/505 , C07K16/283 , C07K2317/34
摘要： The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either FcgammaRllb or FcgammaRlla.
摘要翻译：本发明涉及携带构象鉴别表位（CDE）的新型免疫原和用于产生特异性识别具有非常密切相关同系物的蛋白质的抗体的免疫方法。特别地，本发明涉及对FcgammaR1b或FcγRa1a特异的抗体。

3. 发明申请

WO2008017363A3 IMPROVED IMMUNOASSAY INVOLVING MUTANT ANTIGENS TO REDUCE UNSPECIFIC BINDING 审中-公开
标题翻译：改进的免疫调节涉及突变体抗原以减少不确定性的结合
公开(公告)号：WO2008017363A3
公开(公告)日：2008-04-17
申请号：PCT/EP2007006217
申请日：2007-07-12
申请人： MAX PLANCK GESELLSCHAFT , SUPPREMOL GMBH , JACOB UWE , BREITHAUPT CONSTANZE , HUBER ROBERT
发明人： JACOB UWE , BREITHAUPT CONSTANZE , HUBER ROBERT
IPC分类号： G01N33/68 , G01N33/53
CPC分类号： G01N33/6896 , G01N33/6854 , G01N2333/70503 , G01N2800/285
摘要： The present invention concerns in general the field of antigen-antibody-interaction-based analysis-methods and kits therefore. In particular, the present invention concerns a method for a quantitative in vitro analysis to diagnose, to categorise, to predict and/or to monitor the progression of a condition comprising contacting a sample suspected of containing anti-A-antibodies from a subject to be analysed with native and mutant antigen A, wherein the binding to mutant antigen A helps to eliminate unspecific binding to antigen A and furthermore helps to eliminate individual patient based artefacts, so that clear and unbiased data for the formation of complexes of anti-A-antibodies and antigen A are obtained. The present invention also relates to a kit for carrying out such a method. For example, the antigen is the MOG protein, and it is used as a marker for Multiple Sclerosis.
摘要翻译：因此，本发明一般涉及基于抗原 - 抗体相互作用的分析方法和试剂盒的领域。特别地，本发明涉及用于诊断，分类，预测和/或监测病症进展的定量体外分析的方法，包括将来自受试者的怀疑含有抗A抗体的样品与用天然和突变抗原A进行分析，其中与突变抗原A的结合有助于消除与抗原A的非特异性结合，并且进一步有助于消除单独的基于患者的人工制品，从而形成抗A抗体复合物的清晰和无偏见的数据并获得抗原A. 本发明还涉及一种用于执行这种方法的套件。例如，抗原是MOG蛋白，并且它被用作多发性硬化症的标记物。

4. 发明专利

CA2506068C PHARMACEUTICAL COMPOSITION CONTAINING SFCYR IIB OR SFCYR III 未知
公开(公告)号：CA2506068C
公开(公告)日：2011-09-20
申请号：CA2506068
申请日：2002-11-21
申请人： MAX PLANCK GESELLSCHAFT
发明人： HUBER ROBERT , SONDERMANN PETER , JACOB UWE
IPC分类号： A61K38/17 , C12N15/09 , A61K38/00 , A61P37/00
摘要： The present invention concerns pharmaceutical compositions containing one of the receptors FcyR IIb or FcyR III in a recombinantly produced, soluble form and their use to treat diseases or conditions which are caused by overshooting immune reactions and a pathologically increased formation of antibodies, in particular of autoantibodies. Multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis are particularly important fields of application.

5. 发明专利

DE50212814D1 未知
公开(公告)号：DE50212814D1
公开(公告)日：2008-11-06
申请号：DE50212814
申请日：2002-11-21
申请人： MAX PLANCK GESELLSCHAFT
发明人： HUBER ROBERT , SONDERMANN PETER , JACOB UWE
IPC分类号： A61K38/00 , C12N15/09 , A61K38/17 , A61P37/00
摘要： The present invention concerns pharmaceutical compositions containing one of the receptors FcgammaR IIa, FcgammaR IIb or FcgammaR III in a recombinantly produced, soluble form and their use to treat diseases or conditions which are caused by overshooting immune reactions and a pathologically increased formation of antibodies, in particular of autoantibodies. Multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis are particularly important fields of application.

6. 发明专利

AU2004293184A1 Substance binding human IgG Fc receptor IIb 未知
公开(公告)号：AU2004293184A1
公开(公告)日：2005-06-09
申请号：AU2004293184
申请日：2004-11-26
申请人： MAX PLANCK GESELLSCHAFT
发明人： JACOB UWE , CHIARA CABRELE , HUBER ROBERT , WENDT KERSTIN , MORODER LUIS , SONDERMANN PETER
IPC分类号： C07K14/735 , C07K16/28

7. 发明专利

AU2002366200A1 PHARMACEUTICAL COMPOSITION CONTAINING SFCYR IIB OR SFCYR III 未知
公开(公告)号：AU2002366200A1
公开(公告)日：2003-06-10
申请号：AU2002366200
申请日：2002-11-21
申请人： SUPPREMOL GMBH , MAX PLANCK GESELLSCHAFT
发明人： HUBER ROBERT , SONDERMANN PETER , JACOB UWE
IPC分类号： C12N15/09 , A61K38/00 , A61K38/17 , A61P37/00
摘要： The present invention concerns pharmaceutical compositions containing one of the receptors FcgammaR IIa, FcgammaR IIb or FcgammaR III in a recombinantly produced, soluble form and their use to treat diseases or conditions which are caused by overshooting immune reactions and a pathologically increased formation of antibodies, in particular of autoantibodies. Multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis are particularly important fields of application.

8. 发明专利

AU2002366200A8 Sfcyr iib or sfcyr iii for the treatment of auto-immune diseases 未知
公开(公告)号：AU2002366200A8
公开(公告)日：2003-06-10
申请号：AU2002366200
申请日：2002-11-21
申请人： MAX PLANCK GESELLSCHAFT , SUPPREMOL GMBH
发明人： SONDERMANN PETER , JACOB UWE , HUBER ROBERT
IPC分类号： C12N15/09 , A61K38/00 , A61K38/17 , A61P37/00
摘要： The present invention concerns pharmaceutical compositions containing one of the receptors FcgammaR IIa, FcgammaR IIb or FcgammaR III in a recombinantly produced, soluble form and their use to treat diseases or conditions which are caused by overshooting immune reactions and a pathologically increased formation of antibodies, in particular of autoantibodies. Multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis are particularly important fields of application.

9. 发明专利

CA2547126C SUBSTANCE BINDING HUMAN IGG FC RECEPTOR IIB (FCYRIIB) 未知
公开(公告)号：CA2547126C
公开(公告)日：2014-07-15
申请号：CA2547126
申请日：2004-11-26
申请人： MAX PLANCK GESELLSCHAFT
发明人： HUBER ROBERT , SONDERMANN PETER , JACOB UWE , WENDT KERSTIN , CABRELE CHIARA , MORODER LUIS
IPC分类号： C07K14/735 , A61K39/395 , A61P37/02 , C07K14/705 , C07K16/28 , G01N33/53 , G01N33/564 , G01N33/68
摘要： The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either Fc.gamma.Rllb or Fc.gamma.Rlla.

10. 发明专利

PL1709073T3 Substancja wiążąca receptor IIb Fc ludzkiej IgG (FcγRIIb) 未知
公开(公告)号：PL1709073T3
公开(公告)日：2012-01-31
申请号：PL04798098
申请日：2004-11-26
申请人： MAX PLANCK GESELLSCHAFT
发明人： HUBER ROBERT , SONDERMANN PETER , JACOB UWE , WENDT KERSTIN , CHIARA CABRELE , MORODER LUIS
IPC分类号： C07K16/28 , A61K39/00 , C07K14/735 , C12N15/12 , C12N15/63 , G01N33/53 , G01N33/68

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式